"The
Report Cosentyx (secukinumab) (Rheumatoid Arthritis) - Forecast and
Market Analysis to 2023 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Description
Cosentyx (secukinumab)
(Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints . It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
Novartis is developing a
novel, SC, fully-human, IL-17A mAb known as Cosentyx (secukinumab,
previously known as AIN457) for multiple indications, including RA.
It is currently in Phase III clinical trials for RA in various
countries, including the US, EU, and Japan. It prevents inflammatory
responses, as it neutralizes IL-17A, resulting in the prevention of
bone loss. As of November 2014, Cosentyx is currently undergoing
regulatory review for psoriasis and in development for uveitis,
psoriatic arthritis, ankylosing spondylitis, and asthma.
View
Full Report at http://www.marketresearchreports.biz/analysis/247164
Scope
- Overview of Rheumatoid
Arthritis, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on
Cosentyx including product description, safety and efficacy profiles
as well as a SWOT analysis.
- Sales forecast for Cosentyx
for the top eight countries from 2013 to 2023.
- Sales information covered
for the US, France, Germany, Italy, Spain, the UK, Japan and India.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return.
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid Arthritis.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential.
- Make more informed business
decisions from insightful and in-depth analysis of Cosentyx
performance.
- Obtain sales forecast for
Cosentyx from 2013-2023 in top eight countries (the US, France,
Germany, Italy, Spain, the UK and Japan and India).
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 11
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 15
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 33
4.1.4 Clinical Practice 34
5 Competitive Assessment 40
5.1 Overview 40
6 Unmet Need and Opportunity 42
6.1 Overview 42
6.2 Development of Cost-Effective Therapies 43
6.2.1 Unmet Need 43
6.2.2 Gap Analysis 44
6.2.3 Opportunity 44
6.3 Biomarkers to Predict Responsiveness to Therapy 45
6.3.1 Unmet Need 45
6.3.2 Gap Analysis 47
6.3.3 Opportunity 47
7 Pipeline Assessment 54
7.1 Overview 54
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment